Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.

Ooft SN, Weeber F, Dijkstra KK, McLean CM, Kaing S, van Werkhoven E, Schipper L, Hoes L, Vis DJ, van de Haar J, Prevoo W, Snaebjornsson P, van der Velden D, Klein M, Chalabi M, Boot H, van Leerdam M, Bloemendal HJ, Beerepoot LV, Wessels L, Cuppen E, Clevers H, Voest EE.

Sci Transl Med. 2019 Oct 9;11(513). pii: eaay2574. doi: 10.1126/scitranslmed.aay2574.

PMID:
31597751
2.

The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.

van der Velden DL, Hoes LR, van der Wijngaart H, van Berge Henegouwen JM, van Werkhoven E, Roepman P, Schilsky RL, de Leng WWJ, Huitema ADR, Nuijen B, Nederlof PM, van Herpen CML, de Groot DJA, Devriese LA, Hoeben A, de Jonge MJA, Chalabi M, Smit EF, de Langen AJ, Mehra N, Labots M, Kapiteijn E, Sleijfer S, Cuppen E, Verheul HMW, Gelderblom H, Voest EE.

Nature. 2019 Sep 30. doi: 10.1038/s41586-019-1600-x. [Epub ahead of print]

PMID:
31570881
3.

How I treat MSI cancers with advanced disease.

Kok M, Chalabi M, Haanen J.

ESMO Open. 2019 May 21;4(Suppl 2):e000511. doi: 10.1136/esmoopen-2019-000511. eCollection 2019. Review.

4.

Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S, Wiersma TG, Russell NS, Lalezari F, Schouten PC, Bakker NAM, Ketelaars SLC, Peters D, Lange CAH, van Werkhoven E, van Tinteren H, Mandjes IAM, Kemper I, Onderwater S, Chalabi M, Wilgenhof S, Haanen JBAG, Salgado R, de Visser KE, Sonke GS, Wessels LFA, Linn SC, Schumacher TN, Blank CU, Kok M.

Nat Med. 2019 Jul;25(7):1175. doi: 10.1038/s41591-019-0520-5.

PMID:
31209337
5.

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S, Wiersma TG, Russell NS, Lalezari F, Schouten PC, Bakker NAM, Ketelaars SLC, Peters D, Lange CAH, van Werkhoven E, van Tinteren H, Mandjes IAM, Kemper I, Onderwater S, Chalabi M, Wilgenhof S, Haanen JBAG, Salgado R, de Visser KE, Sonke GS, Wessels LFA, Linn SC, Schumacher TN, Blank CU, Kok M.

Nat Med. 2019 Jun;25(6):920-928. doi: 10.1038/s41591-019-0432-4. Epub 2019 May 13. Erratum in: Nat Med. 2019 Jun 17;:.

PMID:
31086347
6.

Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6)

Rovers KP, Bakkers C, Simkens GAAM, Burger JWA, Nienhuijs SW, Creemers GM, Thijs AMJ, Brandt-Kerkhof ARM, Madsen EVE, Ayez N, de Boer NL, van Meerten E, Tuynman JB, Kusters M, Sluiter NR, Verheul HMW, van der Vliet HJ, Wiezer MJ, Boerma D, Wassenaar ECE, Los M, Hunting CB, Aalbers AGJ, Kok NFM, Kuhlmann KFD, Boot H, Chalabi M, Kruijff S, Been LB, van Ginkel RJ, de Groot DJA, Fehrmann RSN, de Wilt JHW, Bremers AJA, de Reuver PR, Radema SA, Herbschleb KH, van Grevenstein WMU, Witkamp AJ, Koopman M, Haj Mohammad N, van Duyn EB, Mastboom WJB, Mekenkamp LJM, Nederend J, Lahaye MJ, Snaebjornsson P, Verhoef C, van Laarhoven HWM, Zwinderman AH, Bouma JM, Kranenburg O, van 't Erve I, Fijneman RJA, Dijkgraaf MGW, Hemmer PHJ, Punt CJA, Tanis PJ, de Hingh IHJT; Dutch Peritoneal Oncology Group (DPOG); Dutch Colorectal Cancer Group (DCCG).

BMC Cancer. 2019 Apr 25;19(1):390. doi: 10.1186/s12885-019-5545-0.

7.

CoExpresso: assess the quantitative behavior of protein complexes in human cells.

Chalabi MH, Tsiamis V, Käll L, Vandin F, Schwämmle V.

BMC Bioinformatics. 2019 Jan 9;20(1):17. doi: 10.1186/s12859-018-2573-8.

8.

Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma.

Koemans WJ, Chalabi M, van Sandick JW, van Dieren JM, Kodach LL.

Cancer Lett. 2019 Feb 1;442:279-286. doi: 10.1016/j.canlet.2018.11.001. Epub 2018 Nov 9.

PMID:
30419350
9.

Effect of fermentation temperature and different Streptococcus thermophilus to Lactobacillus bulgaricus ratios on Kermanshahi roghan and yoghurt fatty acid profiles.

Mostafaie A, Bahrami G, Chalabi M.

J Dairy Res. 2018 Nov;85(4):472-475. doi: 10.1017/S0022029918000626. Epub 2018 Aug 13.

PMID:
30101732
10.

Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids.

Dijkstra KK, Cattaneo CM, Weeber F, Chalabi M, van de Haar J, Fanchi LF, Slagter M, van der Velden DL, Kaing S, Kelderman S, van Rooij N, van Leerdam ME, Depla A, Smit EF, Hartemink KJ, de Groot R, Wolkers MC, Sachs N, Snaebjornsson P, Monkhorst K, Haanen J, Clevers H, Schumacher TN, Voest EE.

Cell. 2018 Sep 6;174(6):1586-1598.e12. doi: 10.1016/j.cell.2018.07.009. Epub 2018 Aug 9.

11.

Shikonin Production by Callus Culture of Onosma bulbotrichom as Active Pharmaceutical Ingredient.

Bagheri F, Tahvilian R, Karimi N, Chalabi M, Azami M.

Iran J Pharm Res. 2018 Spring;17(2):495-504.

12.

Proteolytic activities of kiwifruit actinidin (Actinidia deliciosa cv. Hayward) on different fibrous and globular proteins: a comparative study of actinidin with papain.

Chalabi M, Khademi F, Yarani R, Mostafaie A.

Appl Biochem Biotechnol. 2014 Apr;172(8):4025-37. doi: 10.1007/s12010-014-0812-7. Epub 2014 Mar 7.

PMID:
24604128
13.

Somatostatin analogs: does pharmacology impact antitumor efficacy?

Chalabi M, Duluc C, Caron P, Vezzosi D, Guillermet-Guibert J, Pyronnet S, Bousquet C.

Trends Endocrinol Metab. 2014 Mar;25(3):115-27. doi: 10.1016/j.tem.2013.11.003. Epub 2014 Jan 7. Review.

PMID:
24405892
14.

Catheter-related bloodstream infections: a prospective observational study of central venous and arterial catheters.

Wittekamp BH, Chalabi M, van Mook WN, Winkens B, Verbon A, Bergmans DC.

Scand J Infect Dis. 2013 Oct;45(10):738-45. doi: 10.3109/00365548.2013.804632. Epub 2013 Jul 5.

PMID:
23826790
15.

Inflammation triggers and sustains a pathological threshold of Ras activity necessary to induce pancreatic tumorigenesis.

Chalabi M, Pyronnet S, Bousquet C.

Clin Res Hepatol Gastroenterol. 2012 Dec;36(6):527-9. doi: 10.1016/j.clinre.2012.06.008. Epub 2012 Aug 9. No abstract available.

PMID:
22883834
16.

Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy.

Bousquet C, Lasfargues C, Chalabi M, Billah SM, Susini C, Vezzosi D, Caron P, Pyronnet S.

J Clin Endocrinol Metab. 2012 Mar;97(3):727-37. doi: 10.1210/jc.2011-2088. Epub 2011 Dec 14. Review.

PMID:
22170729
17.

Periodontopathic bacteria and herpesviruses in chronic periodontitis.

Chalabi M, Rezaie F, Moghim S, Mogharehabed A, Rezaei M, Mehraban B.

Mol Oral Microbiol. 2010 Jun;25(3):236-40. doi: 10.1111/j.2041-1014.2010.00571.x.

PMID:
20536751
18.

Prevalence of Epstein-Barr virus type 1 in patients with chronic periodontitis by nested-PCR.

Moghim SH, Chalabi M, Abed AM, Rezaei F, Tamizifar H.

Pak J Biol Sci. 2007 Dec 15;10(24):4547-50.

PMID:
19093530
19.

Prevalence of Porphyromonas gingivalis and Bacteroides forsythus in chronic periodontitis by multiplex PCR.

Faghri J, Moghim Sh, Abed AM, Rezaei F, Chalabi M.

Pak J Biol Sci. 2007 Nov 15;10(22):4123-7.

PMID:
19090291
20.

EBV and CMV in chronic periodontitis: a prevalence study.

Chalabi M, Moghim S, Mogharehabed A, Najafi F, Rezaie F.

Arch Virol. 2008;153(10):1917-9. doi: 10.1007/s00705-008-0186-7. Epub 2008 Sep 14.

PMID:
18791835
21.

Kiwifruit actinidin: a proper new collagenase for isolation of cells from different tissues.

Mostafaie A, Bidmeshkipour A, Shirvani Z, Mansouri K, Chalabi M.

Appl Biochem Biotechnol. 2008 Feb;144(2):123-31.

PMID:
18456944

Supplemental Content

Loading ...
Support Center